Thyroid Diseases News - LARVOL Sigma

Thyroid Diseases

Welcome, Profile Billing Logout

76 Mechanisms of Action

«1 2...2 3 4 5 6 7 8 9 101112 13 14 »

|||||||||| Enrollment open: A Study of T3 Therapy in Patients With Hypothyroidism (clinicaltrials.gov) - Mar 20, 2013
P2, N=20, Recruiting, Sponsor: Ipe, LLC
Not yet recruiting --> Recruiting

||||||||||  sertraline / Generic mfg., reboxetine / Generic mfg.
Trial completion, Adverse events:  Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. (clinicaltrials.gov) -  Mar 20, 2013
P=N/A, N=35, Completed,  Sponsor: Hadassah Medical Organization
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| Enrollment change: EBIS: The Eindhoven Breech Intervention Study (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=250, Completed, Sponsor: Catharina Ziekenhuis Eindhoven
Recruiting --> Completed N=500 --> 250

|||||||||| Trial completion: EBIS: The Eindhoven Breech Intervention Study (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=250, Completed, Sponsor: Catharina Ziekenhuis Eindhoven
N=500 --> 250 Recruiting --> Completed

||||||||||  Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P2 trial, IO biomarker:  Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) -  Mar 12, 2013
P2, N=25, Recruiting,  Sponsor: National Cancer Institute (NCI)

|||||||||| Enrollment change: Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=60, Completed, Sponsor: Meir Medical Center
Recruiting --> Completed N=50 --> 60

|||||||||| Trial completion: Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=60, Completed, Sponsor: Meir Medical Center
N=50 --> 60 Recruiting --> Completed

||||||||||  Sutent (sunitinib) / Pfizer
Trial completion, Metastases:  THYSU: Thyroid Cancer and Sunitinib (clinicaltrials.gov) -  Feb 26, 2013
P2, N=71, Completed,  Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  everolimus / Generic mfg.
Enrollment change, Metastases:  Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) -  Feb 25, 2013
P2, N=40, Recruiting,  Sponsor: Yonsei University
Active, not recruiting --> Completed N=32 --> 40

|||||||||| New P2 trial: A Study of T3 Therapy in Patients With Hypothyroidism (clinicaltrials.gov) - Feb 25, 2013
P2, N=20, Recruiting, Sponsor: Ipe, LLC

||||||||||  Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion, Metastases:  Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies (clinicaltrials.gov) -  Feb 25, 2013
P1, N=85, Completed,  Sponsor: Exelixis
N=32 --> 40 Active, not recruiting --> Completed

|||||||||| Enrollment change, Metastases: Biological Therapy in Treating Patients With Metastatic Cancer (clinicaltrials.gov) - Feb 20, 2013
P1, N=24, Completed, Sponsor: Duke University
Active, not recruiting --> Completed N=18 --> 24

|||||||||| Trial completion, Metastases: Biological Therapy in Treating Patients With Metastatic Cancer (clinicaltrials.gov) - Feb 20, 2013
P1, N=24, Completed, Sponsor: Duke University
N=18 --> 24 Active, not recruiting --> Completed

||||||||||  thyroxine / Generic mfg.
Enrollment open:  Selenium Supplementation in Pregnancy (clinicaltrials.gov) -  Feb 18, 2013
P4, N=150, Recruiting,  Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  bortezomib / Generic mfg.
Enrollment closed, Metastases:  Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) -  Feb 11, 2013
P2, N=45, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) (clinicaltrials.gov) - Feb 6, 2013
P2, N=165, Completed, Sponsor: Rock Creek Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting N=120 --> 165

||||||||||  sobetirome (QRX 411) / Annovis Bio
New P1 trial:  Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) (clinicaltrials.gov) -  Feb 6, 2013
P1, N=0, Withdrawn,  Sponsor: Thomas S. Scanlan

|||||||||| Trial completion: Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention) (clinicaltrials.gov) - Feb 6, 2013
P2, N=165, Completed, Sponsor: Rock Creek Pharmaceuticals, Inc.
N=120 --> 165 Active, not recruiting --> Completed

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date:  Tocilizumab Treatment in Graves (clinicaltrials.gov) -  Feb 5, 2013
P3, N=32, Recruiting,  Sponsor: Hospital Clinico Universitario de Santiago
Active, not recruiting --> Completed Initiation date: Apr 2011 --> Mar 2012

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open:  Tocilizumab Treatment in Graves (clinicaltrials.gov) -  Feb 5, 2013
P3, N=32, Recruiting,  Sponsor: Hospital Clinico Universitario de Santiago
Initiation date: Apr 2011 --> Mar 2012 Not yet recruiting --> Recruiting

||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases:  A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer (clinicaltrials.gov) -  Feb 5, 2013
P2, N=66, Completed,  Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| New P2 trial, Surgery: Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children? (clinicaltrials.gov) - Jan 29, 2013
P2, N=45, Completed, Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia

|||||||||| Enrollment change: SWETHY: Elastography Interest in the Management of Thyroid Nodules (clinicaltrials.gov) - Jan 23, 2013
P2/3, N=125, Completed, Sponsor: AdministrateurCIC
Active, not recruiting --> Completed N=304 --> 125

|||||||||| Trial completion: SWETHY: Elastography Interest in the Management of Thyroid Nodules (clinicaltrials.gov) - Jan 23, 2013
P2/3, N=125, Completed, Sponsor: AdministrateurCIC
N=304 --> 125 Recruiting --> Completed

|||||||||| Enrollment change: Remission Induction and Sustenance in Graves' Disease 2 (clinicaltrials.gov) - Jan 21, 2013
P4, N=250, Active, not recruiting, Sponsor: Aalborg Universityhospital
Recruiting --> Completed N=200 --> 250

||||||||||  thyroxine / Generic mfg.
New P4 trial:  Effects of L-carnitine on Hypothyroidism (clinicaltrials.gov) -  Jan 14, 2013
P4, N=60, Completed,  Sponsor: Korea University Anam Hospital

||||||||||  sorafenib / Generic mfg.
Trial termination, Metastases:  Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer (clinicaltrials.gov) -  Jan 10, 2013
P2, N=36, Terminated,  Sponsor: National Cancer Institute (NCI)
N=200 --> 250 Active, not recruiting --> Terminated

||||||||||  gefitinib / Generic mfg.
Trial completion, Metastases:  Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Jan 10, 2013
P=N/A, N=40, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Terminated --> Completed

|||||||||| Enrollment change, HEOR: Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer (clinicaltrials.gov) - Jan 8, 2013
P4, N=56, Completed, Sponsor: Copenhagen University Hospital at Herlev
Terminated --> Completed N=100 --> 56

|||||||||| Surgery: Comparing Harmonic Ultrasonic Scalpel to Small Jaw Bipolar Device in Thyroid Surgery (clinicaltrials.gov) - Jan 8, 2013
P=N/A, N=100, Recruiting, Sponsor: National Cancer Centre, Singapore

|||||||||| Trial completion, HEOR: Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer (clinicaltrials.gov) - Jan 8, 2013
P4, N=56, Completed, Sponsor: Copenhagen University Hospital at Herlev
N=100 --> 56 Recruiting --> Completed

|||||||||| Enrollment change, IO biomarker: LITCA;ChiricutaIO: Lipid Metabolic Status in Thyroid Carcinoma (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=52, Completed, Sponsor: Prof. Dr. I. Chiricuta Institute of Oncology
Recruiting --> Completed N=30 --> 52

|||||||||| Trial completion, IO biomarker: LITCA;ChiricutaIO: Lipid Metabolic Status in Thyroid Carcinoma (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=52, Completed, Sponsor: Prof. Dr. I. Chiricuta Institute of Oncology
N=30 --> 52 Recruiting --> Completed

|||||||||| Trial completion, Surgery: Video-assisted Thyroid Surgery and Hypnosis in Thyroid Surgery (clinicaltrials.gov) - Dec 17, 2012
P=N/A, N=130, Completed, Sponsor: Cliniques universitaires Saint-Luc- Universit
Recruiting --> Completed Not yet recruiting --> Completed

||||||||||  ofranergene obadenovec (VB-111) / NanoCarrier, VBL Therap
Enrollment open, Metastases:  Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer (clinicaltrials.gov) -  Dec 16, 2012
P2, N=50, Recruiting,  Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Not yet recruiting --> Completed Active, not recruiting --> Recruiting

|||||||||| New P2 trial: An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT) (clinicaltrials.gov) - Dec 9, 2012
P2, N=115, Not yet recruiting, Sponsor: Alberta Health Services

|||||||||| Enrollment closed: To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer (clinicaltrials.gov) - Dec 9, 2012
P1, N=30, Active, not recruiting, Sponsor: Alberta Health Services
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment change, Metastases: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 29, 2012
P1, N=121, Completed, Sponsor: TopoTarget A/S
Recruiting --> Active, not recruiting N=100 --> 121

|||||||||| Trial completion, Metastases: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 29, 2012
P1, N=121, Completed, Sponsor: TopoTarget A/S
N=100 --> 121 Active, not recruiting --> Completed

|||||||||| New P4 trial: A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours (clinicaltrials.gov) - Nov 27, 2012
P4, N=144, Completed, Sponsor: Genzyme

||||||||||  sorafenib / Generic mfg.
New P2 trial, Metastases:  Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma (clinicaltrials.gov) -  Nov 27, 2012
P2, N=0, Withdrawn,  Sponsor: Eanm Research Ltd

||||||||||  Caprelsa (vandetanib) / Sanofi
Enrollment change:  S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 14, 2012
P1, N=0, Withdrawn,  Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=60 --> 0

||||||||||  doxycycline / Generic mfg.
New P1/2 trial:  Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy (clinicaltrials.gov) -  Nov 14, 2012
P1/2, N=14, Completed,  Sponsor: Sun Yat-sen University

||||||||||  dexamethasone injection / Generic mfg.
Trial completion:  Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients (clinicaltrials.gov) -  Nov 7, 2012
P1, N=50, Completed,  Sponsor: Xiao-Ming Mao
N=60 --> 0 Recruiting --> Completed

||||||||||  cixutumumab (IMC A12) / Eli Lilly
Enrollment closed:  Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) -  Oct 23, 2012
P1, N=19, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Alora (estradiol) / AbbVie
Enrollment change:  A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women (clinicaltrials.gov) -  Oct 10, 2012
P4, N=27, Completed,  Sponsor: Watson Pharmaceuticals
Recruiting --> Active, not recruiting N=35 --> 27

||||||||||  Inlyta (axitinib) / Pfizer
Trial completion, Metastases:  Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer (clinicaltrials.gov) -  Oct 10, 2012
P2, N=52, Completed,  Sponsor: Pfizer
N=35 --> 27 Active, not recruiting --> Completed

||||||||||  Zybrestat (fosbretabulin) / Oncotelic
New P3 trial, Combination therapy:  FACT2: Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (clinicaltrials.gov) -  Oct 3, 2012
P3, N=0, Withdrawn,  Sponsor: OXiGENE

|||||||||| Trial completion: Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T) (clinicaltrials.gov) - Sep 28, 2012
P=N/A, N=100, Completed, Sponsor: Aristotle University Of Thessaloniki
Active, not recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT) (clinicaltrials.gov) - Sep 28, 2012
P=N/A, N=100, Completed, Sponsor: Aristotle University Of Thessaloniki
Recruiting --> Completed Recruiting --> Completed